DEFM14A: HOOKIPA Pharma to Dissolve After Selling Key Programs to Gilead Sciences for $10 Million

HOOKIPA Pharma Inc. is seeking stockholder approval for the sale of its Hepatitis B and HIV programs to Gilead Sciences for up to $10 million, followed by the company's liquidation and dissolution, with an estimated per-share distribution of $1.28 to $1.72 to stockholders.

Summary

• HOOKIPA Pharma Inc. (HOOKIPA) is proposing to sell its Hepatitis B (HB-400) and Human Immunodeficiency Virus (HB-500) programs, including related assets, to Gilead Sciences, Inc. for an aggregate cash consideration of up to $10.0 million.
• The sale price includes an initial $3.0 million payable upon closing and up to $7.0 million in three stages upon successful completion of a three-phase Transfer Plan for the assets.
• Following the asset sale, HOOKIPA intends to liquidate and dissolve, subject to stockholder approval, with an anticipated net proceeds of approximately $7.6 million after expenses and taxes.
• The Board anticipates a distribution to stockholders of approximately $1.28 to $1.72 per share of common stock and Class A common stock, based on 9,799,053 common shares and 2,399,517 Class A common shares outstanding on the record date.
• Any distributions to stockholders are not expected to occur earlier than three years after the filing of the Certificate of Dissolution.
• The company's common stock is expected to be delisted from Nasdaq and trading will be suspended prior to the Certificate of Dissolution filing, with no further market for the stock.
• The Board unanimously approved the Asset Sale and the Dissolution, recommending stockholders vote FOR both proposals and the Adjournment Proposal.
• The decision to sell assets and dissolve follows a strategic review process, driven by limited cash resources, no revenue-generating product candidates, high public company costs, and a competitive marketplace.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the company's decision to dissolve and liquidate, which signifies a failure of its core business strategy and inability to continue as a going concern. While the asset sale provides some return to shareholders, it represents the end of the company's independent operations and future growth potential. The long delay in stockholder distributions and the inherent uncertainties further contribute to the negative outlook.

Positives

• The asset sale provides a mechanism for stockholders to potentially monetize their investment in the company, given historically low trading volumes and a negative stock price trend.
• The Board determined that the asset sale and subsequent dissolution could result in a better return for stockholders than continuing an organic growth strategy, considering the company's financial constraints and market conditions.
• The company received a $19.8 million payment in mid-February 2025 from the Austrian research incentive program, which improved its cash position and the likelihood of a positive recovery for stockholders upon dissolution.

Negatives

• The company is dissolving and liquidating, indicating a cessation of its primary business operations and a failure to achieve a sustainable growth path.
• The estimated distribution of $1.28 to $1.72 per share is subject to significant uncertainties, including potential indemnification claims from Gilead and unforeseen liabilities, which could reduce the final amount.
• Stockholders will not have dissenters' rights of appraisal in connection with the Asset Sale or the Dissolution.
• If the Asset Sale is not completed, the company may incur significant transaction costs without commensurate benefit, potentially damaging business relationships and causing stock price decline.
• The company will cease to have revenue-generating product candidates, a marketing and sales organization, or experience in marketing products after the Asset Sale.
• The company will continue to incur public company reporting expenses until its common stock is deregistered, reducing assets available for distribution.

Risks

• Failure to complete the Asset Sale could harm the business, damage relationships, distract management, and lead to a decline in stock price.
• The amount of net proceeds from the Asset Sale is uncertain and could be materially less than expected due to potential disputes over Transfer Plan completion payments or indemnification claims from Gilead.
• The requirement to reimburse Gilead's expenses (up to $400,000) if a superior proposal is pursued may discourage other potential buyers.
• The Asset Purchase Agreement limits the company's ability to pursue alternatives to the Asset Sale, potentially hindering more favorable transactions.
• The company is exposed to contingent liabilities under the Asset Purchase Agreement's indemnification provisions, which could reduce stockholder distributions.
• The Board did not obtain a third-party fairness opinion, meaning stockholders are relying solely on the Board's judgment regarding the fairness of the consideration.
• Directors and executive officers have interests in the Asset Sale (e.g., accelerated vesting of equity awards) that may differ from general stockholder interests.
• The company may be subject to securities litigation, incurring substantial costs and diverting management attention.
• If stockholders vote against the Dissolution Proposal, it would be very difficult for the company to continue business operations.
• The exact amount or timing of distributions to stockholders is uncertain and could be delayed or reduced by unknown or contingent liabilities, or increased operating costs during winding up.
• The Board retains the right to abandon or modify the Dissolution Plan even after stockholder approval, potentially impacting stockholder value.
• Failure to create an adequate contingency reserve for liabilities could lead to stockholders being held liable for pro rata shares of amounts owed to creditors, up to the amount distributed.
• The tax treatment of liquidating distributions may vary for individual stockholders, and the company has not obtained an IRS ruling or counsel opinion on tax consequences.
• Stockholders may not be able to recognize a loss for federal income tax purposes until the final distribution, which could be many years after dissolution.
• If a liquidating trust is used, interests in it would not be transferable, potentially affecting stockholders' ability to realize value or pay taxes.
• Management of the liquidation process may be turned over to a third party, and directors may resign, potentially impacting control over the process.
• Delisting from Nasdaq will eliminate a public trading market for the common stock, and trading may be very limited prior to delisting.
• Failure to retain appropriate personnel could hinder the success of the Plan of Dissolution.
• Suspension of SEC reporting obligations will limit public information regarding the company's business and dissolution status.

Future Outlook

The company intends to file a Certificate of Dissolution with the Delaware Secretary of State as soon as practicable after the Asset Sale closing and completion of the Transfer Plan, currently expected in late 2025. This will lead to the winding up and liquidation of the company, with distributions to stockholders anticipated no earlier than three years after the dissolution filing. The common stock will be delisted from Nasdaq, and the company will cease periodic reporting obligations. If the dissolution is not approved, the company would use its cash for ongoing operating expenses and the Board would evaluate alternatives, including remaining public or undertaking a going-private transaction.

Management Comments

• The Board believes hosting a virtual meeting enables participation by more stockholders while lowering the cost of conducting the meeting.
• The Board has unanimously approved the Asset Sale and the Dissolution as being in the best interests of the Company and its stockholders.
• Dr. Malte Peters, CEO, stated his view that the Gilead transaction remained the best available option to maximize stockholder value after reviewing the comprehensive strategic process and the company's cash position.

Industry Context

The company operates in the highly competitive biopharmaceutical industry, which is dominated by companies with significantly greater resources. The decision to sell key programs and dissolve reflects the challenges faced by smaller clinical-stage companies in securing sufficient financing for long-term growth and pivotal trials, especially in competitive therapeutic areas like oncology and infectious diseases. The strategic refocus and multiple workforce reductions highlight the intense pressure on cash runway and the need for significant capital to reach value inflection points in drug development.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for a detailed assessment against global benchmarks. It generally notes that the 'marketplace [is] dominated by companies with greater resources than our own' and highlights the 'high cost of being a U.S. public company' as factors influencing the decision to sell assets and dissolve.

Management Changes

Corporate Governance

Legal Proceedings

• No Legal Proceedings or investigations by any Governmental Entity are pending or, to the knowledge of the Sellers, threatened against either Seller (or its properties or assets), current or former directors/officers, or employees/service providers that are material to the Sellers, Programs, or Transferred Assets, or affecting the operation of the Programs or Transferred Assets.
• Neither Seller is, nor since January 1, 2022 has been, subject to any outstanding Order applicable to the Programs or Transferred Assets, and no Order is threatened.

Related Party Transactions

• The Asset Sale is with Gilead Sciences, Inc., which is a holder of greater than five percent of the company's capital stock and a party to the Collaboration Agreement.
• All transactions and agreements entered into by the Sellers with any Related Party (including the Collaboration Agreement and the Transaction Documents) have been made on arms-length terms and conditions.
• No Related Party has or has had any interest in any material asset used in, useful for, or otherwise related to the Programs.

Stakeholder Impact

• **Shareholders:** Will receive an estimated liquidating distribution of $1.28 to $1.72 per share, but not earlier than three years after dissolution. Their shares will be delisted from Nasdaq, and there will be no public trading market. They will lose their investment in a going concern and future growth potential.
• **Employees:** The company has undergone significant workforce reductions (30% in Jan 2024, 20% in Sept 2024, 80% in Nov 2024). Remaining employees will be involved in the winding-up process, with some executive officers receiving accelerated equity vesting and a special dissolution success bonus.
• **Customers/Partners:** The HBV and HIV programs, previously developed in partnership with Gilead, will be fully transferred to Gilead. Other clinical development activities (HB-200, HB-300, HB-700) have been paused or terminated, impacting potential future customers/patients for those programs.
• **Creditors:** The company intends to pay or make provisions for all claims and obligations, including contingent liabilities, and establish a contingency reserve. There is a risk that the reserve may be inadequate, potentially leading to creditors asserting claims against stockholders.
• **Regulatory Authorities:** The company will cease its public reporting obligations with the SEC after deregistration, reducing public information availability.

Next Steps

• Hold a Special Meeting of Stockholders on July 29, 2025, to vote on the Asset Sale Proposal, Dissolution Proposal, and Adjournment Proposal.
• If approved, complete the Asset Sale no later than the fifth business day after all closing conditions are satisfied or waived, anticipated as soon as possible following the Special Meeting.
• Complete the three-phase Transfer Plan for the HBV and HIV programs to Gilead to receive the full $7.0 million in transfer completion payments.
• File a Certificate of Dissolution with the Delaware Secretary of State as soon as practicable following the closing of the Asset Sale and completion of the Transfer Plan (expected late 2025).
• File an application on Form 25 to delist common stock from Nasdaq and withdraw from Section 12(b) registration.
• File a notification on Form 15 to terminate Section 12(g) registration and suspend Section 15(d) reporting obligations.
• Pay or make provisions for all claims and obligations, establish a contingency reserve, and wind up the company's affairs.
• Make liquidating distributions to stockholders, anticipated no earlier than three years after the Certificate of Dissolution filing, and complete all distributions by the tenth anniversary of the Effective Date.

Key Dates

Recommendation

Keywords

Asset Sale, Dissolution, Liquidation, Biopharmaceutical, SEC Filing, Gilead Sciences, HBV Program, HIV Program, Corporate Governance, Risk Management, Strategic Alternatives, Shareholder Value, Nasdaq Delisting